dr_h
Member
- Reaction score
- 0
Dr. Erich Mohr Appointed Chairman of TrichoScience
February 2, 2010 – Vancouver BC. TrichoScience Innovations Inc.
(TrichoScience) has announced the appointment of Dr. Erich Mohr
(PhD, R.Psych) as the Company's new Chairman of the Board of
Directors, effective immediately. Dr. Mohr also serves as
Chairman and CEO of MedGenesis Therapeutix Inc., a company he
founded in 2006.
Dr. Mohr, who was a Professor of Medicine and Psychology at the
University of Ottawa until 1997, has over 25 years of experience
in experimental therapeutics of CNS disorders. He is credited
with over 150 publications, books, book chapters and abstracts
and has edited the, Handbook of Clinical Trials: The
neurobehavioral approach. Dr. Mohr has chaired and/or served
on several regulatory advisory panels for the approval of new
products for the treatment of neurodegenerative disease. He is
the former Chairman and Chief Executive Officer of CroMedica
Global Inc., which was merged with PRA International in 2002,
and co-founder of several biotechnology companies. Prior to his
founding of MedGenesis, he served as Chief Scientific Officer
for PRA International. PRA is one of the top five contract
research organizations in the world. Over the course of his
career, Dr. Mohr has overseen and/or participated in dozens of
clinical development programs resulting in a number of approved
drugs.
In announcing the appointment, former TrichoScience Chairman,
Dr. David McLean, said, "Dr. Mohr's acceptance of the Board
Chairmanship of TrichoScience marks an important milestone in
the development of our Company. He brings a depth of invaluable
experience that will help shape and guide the Company as it
heads into one of its most important periods of growth and
maturity. His knowledge of and direct participation in both
clinical trials and the regulatory approvals' process brings a
level of hands-on experience and a base of knowledge that will
be of significant benefit to the Company at this time."
Concurrent with Dr. Mohr's appointment, Dr. McLean has been
named Chairman of TrichoScience's new Corporate Advisory Board.
About TrichoScience
TrichoScience Innovations Inc. (TrichoScience) is a
privately-held life sciences company based in Vancouver,
Canada. The company is developing a new hair cell replication
technique that has the potential to become the world's first
non-surgical, permanent cure for pattern baldness and general
hair loss in both men and women. The procedure, a non-surgical,
cellular implantation method that replicates a patient's hair
cells from their own healthy hair follicles, is being developed
by a team of recognized research scientists and medical experts
in the fields of hair growth, hair biology and dermatology.
Patents covering the procedure have been issued in a number of
international jurisdictions and are patent-pending in other
major countries worldwide.
The TrichoScience procedure is not yet commercially available
and is subject to human clinical trials followed by regulatory
submission, review and approvals in Canada, Europe and the
United States.
February 2, 2010 – Vancouver BC. TrichoScience Innovations Inc.
(TrichoScience) has announced the appointment of Dr. Erich Mohr
(PhD, R.Psych) as the Company's new Chairman of the Board of
Directors, effective immediately. Dr. Mohr also serves as
Chairman and CEO of MedGenesis Therapeutix Inc., a company he
founded in 2006.
Dr. Mohr, who was a Professor of Medicine and Psychology at the
University of Ottawa until 1997, has over 25 years of experience
in experimental therapeutics of CNS disorders. He is credited
with over 150 publications, books, book chapters and abstracts
and has edited the, Handbook of Clinical Trials: The
neurobehavioral approach. Dr. Mohr has chaired and/or served
on several regulatory advisory panels for the approval of new
products for the treatment of neurodegenerative disease. He is
the former Chairman and Chief Executive Officer of CroMedica
Global Inc., which was merged with PRA International in 2002,
and co-founder of several biotechnology companies. Prior to his
founding of MedGenesis, he served as Chief Scientific Officer
for PRA International. PRA is one of the top five contract
research organizations in the world. Over the course of his
career, Dr. Mohr has overseen and/or participated in dozens of
clinical development programs resulting in a number of approved
drugs.
In announcing the appointment, former TrichoScience Chairman,
Dr. David McLean, said, "Dr. Mohr's acceptance of the Board
Chairmanship of TrichoScience marks an important milestone in
the development of our Company. He brings a depth of invaluable
experience that will help shape and guide the Company as it
heads into one of its most important periods of growth and
maturity. His knowledge of and direct participation in both
clinical trials and the regulatory approvals' process brings a
level of hands-on experience and a base of knowledge that will
be of significant benefit to the Company at this time."
Concurrent with Dr. Mohr's appointment, Dr. McLean has been
named Chairman of TrichoScience's new Corporate Advisory Board.
About TrichoScience
TrichoScience Innovations Inc. (TrichoScience) is a
privately-held life sciences company based in Vancouver,
Canada. The company is developing a new hair cell replication
technique that has the potential to become the world's first
non-surgical, permanent cure for pattern baldness and general
hair loss in both men and women. The procedure, a non-surgical,
cellular implantation method that replicates a patient's hair
cells from their own healthy hair follicles, is being developed
by a team of recognized research scientists and medical experts
in the fields of hair growth, hair biology and dermatology.
Patents covering the procedure have been issued in a number of
international jurisdictions and are patent-pending in other
major countries worldwide.
The TrichoScience procedure is not yet commercially available
and is subject to human clinical trials followed by regulatory
submission, review and approvals in Canada, Europe and the
United States.